Tavaborole
- Generic Name
- Tavaborole
- Brand Names
- Kerydin
- Drug Type
- Small Molecule
- Chemical Formula
- C7H6BFO2
- CAS Number
- 174671-46-6
- Unique Ingredient Identifier
- K124A4EUQ3
Overview
Tavaborale is a novel, boron-based topical antifungal medication for the treatment of onychomycosis, a fungal infection of the nail and nail bed due to Trichophyton rubrum or Trichophyton mentagrophytes infection. Tavaborole functions by inhibiting Leucyl-tRNA synthetase, or LeuRS, an essential fungal enzyme required for protein synthesis and for the catalysis of ATP-dependent ligation of L-leucine to tRNA(Leu).
Background
Tavaborale is a novel, boron-based topical antifungal medication for the treatment of onychomycosis, a fungal infection of the nail and nail bed due to Trichophyton rubrum or Trichophyton mentagrophytes infection. Tavaborole functions by inhibiting Leucyl-tRNA synthetase, or LeuRS, an essential fungal enzyme required for protein synthesis and for the catalysis of ATP-dependent ligation of L-leucine to tRNA(Leu).
Indication
Indicated for the treatment of onychomycosis (a fungal infection) of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes.
Associated Conditions
- Onychomycosis of the Toenails caused by Trichophyton mentagrophytes
- Onychomycosis of the Toenails caused by Trichophyton rubrum
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2018/01/23 | Phase 4 | Completed | |||
2008/05/19 | Phase 2 | Completed | |||
2008/05/19 | Phase 2 | Completed | |||
2008/05/19 | Phase 1 | Completed | |||
2008/05/19 | Phase 2 | Completed |
FDA Approved Products
Product Name | Manufacturer | Route | Strength | Approved | NDC Code |
|---|---|---|---|---|---|
Tavaborole | Chartwell RX, LLC | TOPICAL | 43.5 mg in 1 mL | 2023/09/15 | 62135-663 |
TAVABOROLE | Cipla USA Inc. | TOPICAL | 43.5 mg in 1 mL | 2024/01/09 | 69097-686 |
Tavaborole | Padagis US LLC | TOPICAL | 43.5 mg in 1 mL | 2021/01/11 | 0574-0157 |
Tavaborole | Amneal Pharmaceuticals NY LLC | TOPICAL | 43.5 mg in 1 mL | 2019/06/15 | 69238-1657 |
TAVABOROLE | Aleor Dermaceuticals Limited | TOPICAL | 43.5 mg in 1 mL | 2021/12/01 | 71589-010 |
Tavaborole | Bryant Ranch Prepack | TOPICAL | 43.5 mg in 1 mL | 2022/02/23 | 63629-8704 |
Tavaborole | Alembic Pharmaceuticals Inc. | TOPICAL | 43.5 mg in 1 mL | 2023/12/15 | 62332-467 |
TAVABOROLE | Taro Pharmaceuticals U.S.A., Inc. | TOPICAL | 43.5 mg in 1 mL | 2019/05/28 | 51672-1397 |
Tavaborole | Zydus Lifesciences Limited | TOPICAL | 43.5 mg in 1 mL | 2023/04/12 | 70771-1826 |
Tavaborole | Encube Ethicals Private Limited | TOPICAL | 43.5 mg in 1 mL | 2020/10/29 | 21922-020 |
EMA Approved Products
Medicine Name | EMA Number | Auth. Holder | Country | Drug Type | Status | Issued | Opinion | Revision |
|---|
No EMA products found
No EMA products found for this drug
Singapore Approved Products
Product Name | Manufacturer | Dosage Form | Strength | Approved | Approval No. | Online |
|---|
No Singapore products found
No Singapore products found for this drug
China Approved Products
Product Name | Approval No. | Manufacturer | Dosage Form | Trade Name | Strength | Type | Status | Date | Import |
|---|
No China products found
No China products found for this drug
Australia Approved Products
Product Name | ARTG ID | Sponsor | Status | Reg. Date | Ingredient |
|---|
No Australia products found
No Australia products found for this drug